早在19世纪,Fowler液,即三氧化二砷(arsenic trioxide,ATO)就被用于慢性髓细胞白血病(chronic myeloid leukemia,CML)的治疗,在化疗药物问世之前,ATO一直是治疗CML的主要药物,单用ATO 2周可使74%的慢性期CML患者获得完全血液学缓解〔1-2〕。由于其独特的作用机制,即使在酪氨酸激酶抑制剂时代,ATO仍可在CML的治疗中发挥独特的作用〔3-4〕。本文就近年来ATO治疗CML的研究进展作一综述。 As early as the 19th century, Fowler’s solution, arsenic trioxide (ATO), has been used for the treatment of chronic myeloid leukemia (CML). Until the advent of chemotherapeutic drugs, ATO has been the mainstay of treatment for CML 74% of patients with chronic phase CML achieved complete hematologic response over 2 weeks with ATO [1-2]. Due to its unique mechanism of action, ATO can play a unique role in the treatment of CML even in the era of tyrosine kinase inhibitors [3-4]. This article reviews the progress of ATO in the treatment of CML in recent years.